The success of market access lies in an early recognition of clinical, economic and procedural hurdles before the market access procedure begins. The daily practice of the health care environment teaches us that budget constraints cause more and more difficulties for new products and therapies to enter the health insurance system. Daily practice also teaches us that often the market access procedure is underestimated and that health authority’s decisions regularly include restrictions in use for a new treatment.
Based on our > 24 years of experience, we promote an adequate strategic scan and analysis of available data beore the submission of a reimbursement request. Though this preparation may cost time and effort, it shows opportunities for anticipation and may save time and disappointment in conclusion of the procedure.